New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 4, 2014
08:50 EDTABIOARCA Biopharma prices $9M common stock and warrant offering
ARCA Biopharma announced that it has priced its previously announced public offering of common stock and warrants at a price of $1.70 for each share of common stock and a related warrant to purchase 0.25 shares of common stock, for gross proceeds of $8.7 million, prior to deducting underwriting discounts and commissions and offering expenses of the Company. Dawson James Securities, Inc. is acting as the sole book-running manager for the offering.
News For ABIO From The Last 14 Days
Check below for free stories on ABIO the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 18, 2014
08:34 EDTABIOARCA Biopharma announces GENETIC-AF CTA accepted by Health Canada
ARCA biopharma announced that the company’s Clinical Trial Application for the GENETIC-AF clinical trial evaluating GencaroTM as a potential treatment for atrial fibrillation has been accepted by Health Canada. ARCA anticipates that clinical trial sites in Canada will be active in Q4. ARCA is evaluating Gencaro as a potential treatment for AF in the Phase 2B/3 GENETIC-AF clinical trial, which is currently enrolling patients in the U.S. ARCA has identified common genetic variations that it believes predict individual patient response to Gencaro, giving it potential to be the first genetically targeted therapy for the prevention of atrial fibrillation.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use